A Scientific Approach to Pandemic Preparedness
A
A
SCIENTIFIC
SCIENTIFIC
APPROACH
APPROACH
TO
TO
PANDEMIC
PANDEMIC
PREPAREDNESS
PREPAREDNESS
W
H
O
R
&
D
B
l
u
e
p
r
i
n
t
C
o
n
s
u
l
t
a
t
i
o
n
A
S
c
i
e
n
t
i
f
i
c
F
r
a
m
e
w
o
r
k
f
o
r
E
p
i
d
e
m
i
c
a
n
d
P
a
n
d
e
m
i
c
R
e
s
e
a
r
c
h
P
r
e
p
a
r
e
d
n
e
s
s
S
c
i
e
n
t
i
f
i
c
o
p
p
o
r
t
u
n
i
t
i
e
s
t
o
a
c
h
i
e
v
e
f
a
s
t
a
n
d
e
q
u
i
t
a
b
l
e
a
c
c
e
s
s
t
o
h
i
g
h
-
q
u
a
l
i
t
y
a
n
d
t
r
u
s
t
e
d
v
a
c
c
i
n
e
s
f
o
r
f
u
t
u
r
e
p
a
n
d
e
m
i
c
s
O
c
t
o
b
e
r
2
4
,
2
0
2
3
B
a
r
n
e
y
S
.
G
r
a
h
a
m
,
M
D
,
P
h
D
D
i
r
e
c
t
o
r
o
f
D
a
v
i
d
S
a
t
c
h
e
r
G
l
o
b
a
l
H
e
a
l
t
h
E
q
u
i
t
y
I
n
s
t
i
t
u
t
e
P
r
o
f
e
s
s
o
r
o
f
M
e
d
i
c
i
n
e
a
n
d
M
i
c
r
o
b
i
o
l
o
g
y
,
B
i
o
c
h
e
m
i
s
t
r
y
,
I
m
m
u
n
o
l
o
g
y
M
o
r
e
h
o
u
s
e
S
c
h
o
o
l
o
f
M
e
d
i
c
i
n
e
A
t
l
a
n
t
a
,
G
A
Disclosures
•
Vaccine Inventor
•
Coronaviruses
•
Respiratory syncytial virus
•
Influenza virus
•
Nipah and other paramyxoviruses
•
Zika
•
Monoclonal Antibody Inventor
•
Ebola
•
SARS-CoV-2 and other coronaviruses
•
Scientific Advisory Boards
•
Icosavax
•
Vaccine Company, Inc.
•
Third Rock Ventures, Inc. Foundry
•
Consultant
•
GSK
•
Pfizer
•
Janssen
•
Sanofi
•
Merck
•
AstroZeneca
•
Exevir
New Human Viral Pathogens in the 20
th
Century
Woolhouse MEJ et al Proc R Soc B 2008; 275:2111
New families
plateauing
New species
linear
Outbreaks
•
SARS-CoV-1
•
H5N1 influenza
•
H1N1 influenza
•
MERS
•
Chikungunya
•
Ebola
•
Marburg
•
Zika
•
Nipah
•
EV-D68
•
SARS-CoV-2
•
Monkeypox
21
st
Century Viral* Threats and Needs
Could be better
•
Influenza
•
Mumps
•
Yellow Fever
•
Filoviruses
Unsolved Problems
•
HIV
•
HCV
•
Dengue and other flaviviruses
•
Alphaviruses
•
Norovirus and other
nonenveloped viruses
•
Bunyaviruses
•
CMV and other herpesviruses
•
Rapid response approach for
Paramyxoviruses
•
Polyomaviruses
•
Other emerging infections
*Not to mention malaria, Tb, and all the virulent or untreatable bacteria, fungi, and parasites
Viral Taxonomy 2023
•
6 realms
•
10 kingdoms
•
17 phyla
•
2 subphyla
•
40 classes
•
72 orders
•
8 suborders
•
264 families
•
182 subfamilies
•
2818 genera
•
84 subgenera
•
11273 species
~150 viruses from 26 families
recognized as human pathogens with
potential for person-to-person
spread
P
r
o
t
o
t
y
p
e
P
a
t
h
o
g
e
n
A
p
p
r
o
a
c
h
f
o
r
P
a
n
d
e
m
i
c
P
r
e
p
a
r
e
d
n
e
s
s
Graham & Sullivan.
Nature Immunology 2018
•
Pathogen biology, product
development, preclinical and clinical
evaluation supported by global
governance and pre-established
relationships with industry, regulatory
authorities, and public health systems
•
~150 viruses from 26 families known
to infect humans with some potential
for increased human-to-human
transmission and virulence
•
Develop vaccines for ~30 prototype
viruses through phase 1
•
Develop vaccine candidates (&
reagents) for other ~120 through
animal testing
Pandemic Preparedness
•
Know what’s coming
•
Virus discovery
•
Surveillance – humans, animals, and vectors
•
Know what to do
•
Virus characteristics including pathogenesis
•
Basis of immunity – identify antigen target
•
Antigen design and delivery
•
Know how to make biomedical countermeasures
•
Reagents including rapid mAb identification and production
•
Diagnostics
•
Antivirals – preventive and therapeutic
•
Vaccines
•
Animal models
•
Know how to deploy interventions rapidly on a global scale
•
Maintenance and geographic distribution of manufacturing and clinical facilities – scale-up capacity
•
Organization of governments, agencies, industry, academia, and nonprofit organizations
•
Coordination of regulatory processes and requirements
•
Communication with the public
Global COVID-19 Vaccine Landscape
Recombinant proteins
or subdomains
Whole-inactivated virus
Nucleic acid
Recombinant Vectors
Source: WHO 14 February 2023
1
9
9
V
a
c
c
i
n
e
C
a
n
d
i
d
a
t
e
s
i
n
P
r
e
-
c
l
i
n
i
c
a
l
E
v
a
l
u
a
t
i
o
n
1
7
8
V
a
c
c
i
n
e
C
a
n
d
i
d
a
t
e
s
i
n
C
l
i
n
i
c
a
l
E
v
a
l
u
a
t
i
o
n
Live-attenuated virus
Nanoparticle display of
structurally defined proteins
Recombinant or chimeric viruses
Peptides
Virus-like particles
Slide 8
F
i
n
d
i
n
g
G
e
n
e
r
a
l
i
z
a
b
l
e
A
p
p
r
o
a
c
h
e
s
a
n
d
B
r
e
a
k
t
h
r
o
u
g
h
s
Successes
Structure-based antigen design
Self-assembling nanoparticle display
Nucleic acid, vector, or protein delivery
Single-cell analysis
Targeting antibody lineages
Barriers to Pandemic Preparedness
Antigenic diversity
Immunodominance
Durable responses
Mucosal immunity
Immune evasion
Potential for enhanced disease
Glycan shield
Integration and latency
S
t
r
u
c
t
u
r
e
o
f
P
r
e
f
u
s
i
o
n
R
S
V
F
G
l
y
c
o
p
r
o
t
e
i
n
P
o
s
t
f
u
s
i
o
n
P
r
e
f
u
s
i
o
n
T
a
r
g
e
t
i
n
g
r
i
g
h
t
a
n
t
i
g
e
n
i
c
s
i
t
e
m
a
t
t
e
r
s
W
e
e
k
0
W
e
e
k
1
Emily Phung, Lauren Chang
DS-Cav1
(Pre-F)
MEDI7510
(Post-F)
F
i
n
d
i
n
g
G
e
n
e
r
a
l
i
z
a
b
l
e
A
p
p
r
o
a
c
h
e
s
Successes
Virus-like particles
Whole-inactivated
Live-attenuated
Barriers to pandemic preparedness
Multiple serotypes
Structure and antigen definition
Mucosal immunity
F
i
n
d
i
n
g
G
e
n
e
r
a
l
i
z
a
b
l
e
A
p
p
r
o
a
c
h
e
s
Successes
Replication-defective virus
Live-attenuated
Protein subunit
Barriers to pandemic preparedness
Structure and antigen definition
Mucosal immunity
Integration and latency
F
i
n
d
i
n
g
G
e
n
e
r
a
l
i
z
a
b
l
e
A
p
p
r
o
a
c
h
e
s
Successes
Live-attenuated
Virus-like particle
Barriers to pandemic preparedness
Antigen structure
Antibody-dependent enhancement
Pandemic Response
•
Early detection
•
Sequence availability
•
Epidemiology
•
Point of care diagnostics
•
Maintenance of public health infrastructure and reporting
•
Rapid production of
fit-for-purpose
products
•
Use s
train-matched antigens for vaccines
•
mAbs for diagnostics and therapy
•
Antivirals
•
Agent-specific animal models
•
Deploy
•
Will require prior planning and agreements between governments, between agencies within governments,
between governments and non-government organizations with methods of coordination and communication
•
Public-private agreements between nonprofits, philanthropists, academia, and industry
Take Home Messages
•
We have the science and technology to solve most future problems but are
lacking in the areas of policy and practice
•
Need consensus on global coordination, communication, and governance
•
Equitable distribution of basic science, translational science and
manufacturing is critical to solve local problems before they become global
•
Investment in basic research
•
Surveillance needs support for prospective cohorts and sequencing facilities
•
Distributive manufacturing is feasible but needs small market business models
•
Pandemic response will usually require strain-matched products
•
Prior generalizable solutions
•
Emphasis on speed and global coverage
Barney S. Graham, MD, PhD, outlines a scientific framework for epidemic and pandemic research preparedness to achieve fast and equitable access to high-quality vaccines for future pandemics. The discussion covers new human viral pathogens, 21st-century viral threats, viral taxonomy, and a prototype pathogen approach, emphasizing the importance of global governance and collaboration with industry and regulatory authorities.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
A SCIENTIFICAPPROACHTOPANDEMICPREPAREDNESS WHO R&D Blueprint Consultation A Scientific Framework for Epidemic and Pandemic Research Preparedness Scientific opportunities to achieve fast and equitable access to high-quality and trusted vaccines for future pandemics October 24, 2023 Barney S. Graham, MD, PhD Director of David Satcher Global Health Equity Institute Professor of Medicine and Microbiology, Biochemistry, Immunology Morehouse School of Medicine Atlanta, GA
Disclosures Vaccine Inventor Coronaviruses Respiratory syncytial virus Influenza virus Nipah and other paramyxoviruses Zika Monoclonal Antibody Inventor Ebola SARS-CoV-2 and other coronaviruses Scientific Advisory Boards Icosavax Vaccine Company, Inc. Third Rock Ventures, Inc. Foundry Consultant GSK Pfizer Janssen Sanofi Merck AstroZeneca Exevir
New Human Viral Pathogens in the 20th Century New species linear New families plateauing Woolhouse MEJ et al Proc R Soc B 2008; 275:2111
21st Century Viral* Threats and Needs Outbreaks SARS-CoV-1 H5N1 influenza H1N1 influenza MERS Chikungunya Ebola Marburg Zika Nipah EV-D68 SARS-CoV-2 Monkeypox Unsolved Problems Could be better Influenza Mumps Yellow Fever Filoviruses HIV HCV Dengue and other flaviviruses Alphaviruses Norovirus and other nonenveloped viruses Bunyaviruses CMV and other herpesviruses Rapid response approach for Paramyxoviruses Polyomaviruses Other emerging infections *Not to mention malaria, Tb, and all the virulent or untreatable bacteria, fungi, and parasites
Viral Taxonomy 2023 6 realms 10 kingdoms 17 phyla 2 subphyla 40 classes 72 orders 8 suborders 264 families 182 subfamilies 2818 genera 84 subgenera 11273 species ~150 viruses from 26 families recognized as human pathogens with potential for person-to-person spread
Prototype Pathogen Approach for Pandemic Preparedness Prototype Pathogen Approach for Pandemic Preparedness Pathogen biology, product development, preclinical and clinical evaluation supported by global governance and pre-established relationships with industry, regulatory authorities, and public health systems ~150 viruses from 26 families known to infect humans with some potential for increased human-to-human transmission and virulence Develop vaccines for ~30 prototype viruses through phase 1 Develop vaccine candidates (& reagents) for other ~120 through animal testing Graham & Sullivan. Nature Immunology 2018
Pandemic Preparedness Know what s coming Virus discovery Surveillance humans, animals, and vectors Know what to do Virus characteristics including pathogenesis Basis of immunity identify antigen target Antigen design and delivery Know how to make biomedical countermeasures Reagents including rapid mAb identification and production Diagnostics Antivirals preventive and therapeutic Vaccines Animal models Know how to deploy interventions rapidly on a global scale Maintenance and geographic distribution of manufacturing and clinical facilities scale-up capacity Organization of governments, agencies, industry, academia, and nonprofit organizations Coordination of regulatory processes and requirements Communication with the public
Global COVID-19 Vaccine Landscape 199 Vaccine Candidates in Pre-clinical Evaluation 178 Vaccine Candidates in Clinical Evaluation Nanoparticle display of structurally defined proteins Nucleic acid Whole-inactivated virus Live-attenuated virus Recombinant Vectors Recombinant or chimeric viruses Virus-like particles Recombinant proteins or subdomains Peptides Source: WHO 14 February 2023 Slide 8
Finding Generalizable Approaches and Breakthroughs Finding Generalizable Approaches and Breakthroughs Successes Structure-based antigen design Self-assembling nanoparticle display Nucleic acid, vector, or protein delivery Single-cell analysis Targeting antibody lineages Barriers to Pandemic Preparedness Antigenic diversity Immunodominance Durable responses Mucosal immunity Immune evasion Potential for enhanced disease Glycan shield Integration and latency
Structure of Prefusion RSV F Glycoprotein Structure of Prefusion RSV F Glycoprotein Prefusion Postfusion
Targeting right antigenic site matters Targeting right antigenic site matters Week 0 Week 1 Pre-F Dual DS-Cav1 (Pre-F) Post-F MEDI7510 (Post-F) Pre-F Post-F Emily Phung, Lauren Chang
Finding Generalizable Approaches Finding Generalizable Approaches Successes Virus-like particles Whole-inactivated Live-attenuated Barriers to pandemic preparedness Multiple serotypes Structure and antigen definition Mucosal immunity
Finding Generalizable Approaches Finding Generalizable Approaches Successes Replication-defective virus Live-attenuated Protein subunit Barriers to pandemic preparedness Structure and antigen definition Mucosal immunity Integration and latency
Finding Generalizable Approaches Finding Generalizable Approaches Successes Live-attenuated Virus-like particle Barriers to pandemic preparedness Antigen structure Antibody-dependent enhancement
Pandemic Response Early detection Sequence availability Epidemiology Point of care diagnostics Maintenance of public health infrastructure and reporting Rapid production of fit-for-purpose products Use strain-matched antigens for vaccines mAbs for diagnostics and therapy Antivirals Agent-specific animal models Deploy Will require prior planning and agreements between governments, between agencies within governments, between governments and non-government organizations with methods of coordination and communication Public-private agreements between nonprofits, philanthropists, academia, and industry
Take Home Messages We have the science and technology to solve most future problems but are lacking in the areas of policy and practice Need consensus on global coordination, communication, and governance Equitable distribution of basic science, translational science and manufacturing is critical to solve local problems before they become global Investment in basic research Surveillance needs support for prospective cohorts and sequencing facilities Distributive manufacturing is feasible but needs small market business models Pandemic response will usually require strain-matched products Prior generalizable solutions Emphasis on speed and global coverage
